Protagonist Therapeutics, Inc.
(NASDAQ : PTGX)

( )
PTGX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
1.31%353.031.2%$871.11m
AMGNAmgen Inc.
-0.53%194.881.2%$564.77m
CELGCelgene Corporation
-0.54%85.231.2%$555.79m
GILDGilead Sciences, Inc.
-0.16%77.260.9%$499.41m
SRPTSarepta Therapeutics, Inc.
-1.97%136.6816.6%$376.94m
VRTXVertex Pharmaceuticals Incorporated
0.40%181.221.9%$331.68m
REGNRegeneron Pharmaceuticals, Inc.
-0.79%364.752.6%$305.25m
ILMNIllumina, Inc.
-1.63%301.993.5%$267.19m
BLUEBluebird Bio, Inc.
-1.83%177.3015.7%$219.07m
NKTRNektar Therapeutics
0.00%47.795.6%$188.00m
ALXNAlexion Pharmaceuticals, Inc.
-0.95%134.582.0%$175.68m
FMIFoundation Medicine, Inc.
0.00%136.708.8%$168.36m
EXASExact Sciences Corporation
1.41%64.6625.4%$159.06m
BMRNBioMarin Pharmaceutical Inc.
-0.85%102.734.4%$138.72m
EXELExelixis, Inc.
-3.61%21.076.4%$137.74m

Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.